Marinus Pharmaceuticals (NASDAQ:MRNS) Issues Quarterly Earnings Results

Marinus Pharmaceuticals (NASDAQ:MRNS) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.01), Bloomberg Earnings reports.

Shares of MRNS traded up $0.03 during mid-day trading on Friday, hitting $1.19. 1,072,588 shares of the company’s stock were exchanged, compared to its average volume of 1,810,597. The firm’s fifty day simple moving average is $3.10. Marinus Pharmaceuticals has a twelve month low of $0.77 and a twelve month high of $10.54. The firm has a market capitalization of $60.96 million, a PE ratio of -1.32 and a beta of 2.89.

In other news, CFO Edward F. Smith sold 24,211 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $5.03, for a total transaction of $121,781.33. Following the transaction, the chief financial officer now owns 20,097 shares in the company, valued at approximately $101,087.91. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 5.10% of the company’s stock.

Several research firms have weighed in on MRNS. Zacks Investment Research upgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 3rd. LADENBURG THALM/SH SH reiterated a “buy” rating and issued a $3.00 price objective on shares of Marinus Pharmaceuticals in a research note on Friday. Cantor Fitzgerald reiterated a “buy” rating and issued a $22.00 price objective on shares of Marinus Pharmaceuticals in a research note on Wednesday, May 1st. Mizuho dropped their price objective on shares of Marinus Pharmaceuticals from $5.00 to $1.70 and set a “neutral” rating on the stock in a research note on Tuesday, July 23rd. Finally, ValuEngine upgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $11.39.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Further Reading: 52-Week High/Low

Earnings History for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.